Second line initiation of insulin compared with DPP-4 inhibitors after metformin monotherapy is associated with increased risk of all-cause mortality, cardiovascular events, and severe hypoglycemia

详细信息    查看全文

• 作者：Thomas Nystr&ouml ; m^a ; Johan Bodegard^b ; ^{johan.bodegard@astrazeneca.com} ; David Nathanson^a ; Marcus Thuresson^c ; Anna Norhammar^d ; ^e ; Jan W. Eriksson^f
• 关键词：Insulin ; Type 2 diabetes ; Dipeptidyl peptidase-4 inhibitor ; Cardiovascular disease ; Hypoglycemia ; Outcome
• 刊名：Diabetes Research and Clinical Practice
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：123
• 期：Complete
• 页码：199-208
• 全文大小：758 K
• 卷排序：123

文摘

Nationwide observational study to compare clinical outcomes of different treatments. Initiation of insulin after metformin monotherapy is relatively common in Sweden. Insulin was associated with risk of hypoglycemia, CVD and death compared to DDP-4i.